Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

TiDrugArchitectures

Financiado

Highly Competent and Safe Titanium IV Therapeutic Frameworks that are Cancer Ta...

Highly Competent and Safe Titanium IV Therapeutic Frameworks that are Cancer Targeted based on Complex 1 2 and 3D Chemical Architectures This proposal aims to develop custom designed anticancer therapeutic frameworks that are effective, stable, safe, and tumor targeted, based on the biocompatible TiIV metal. The Tshuva group has established that water stable phenol... ver más

31/05/2022

THE HEBREW UNIVERS...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-05-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-CoG-2015: ERC Consolidator Grant

I+D

Cerrada hace 9 años

0% 100%

2 Participantes

THE HEBREW UNIVERSITY OF JER...

2.00M€ | Lider

MS METALSYSTEM

259.30K€ | Participante

Proyectos interesantes

PID2021-125746OA-I00 HACIA UNA TERAPIA DIRIGIDA CONTRA EL CANCER: UTILIZACION DE... 157K€ Cerrado

MET-EFFECT Metal complexes of a naturally inspired framework functional... 764K€ Cerrado

BiorthoCat-Immuno Biorthogonal Catalytic Scaffold for in situ Personalized Can... 207K€ Cerrado

CTQ2012-32929 DESARROLLO DE UN SISTEMA INTELIGENTE DE LIBERACION DUAL (TER... 125K€ Cerrado

CTQ2008-02064 ACTIVIDAD ANTITUMORAL E INHIBIDORA DE TELOMERASAS DE COMPUES... 83K€ Cerrado

Co-CaReD In-cell Redox Catalysis by Co(III) Metallodrugs as New Tools... 165K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 72 meses Fecha Inicio: 2016-05-25
Fecha Fin: 2022-05-31

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto This proposal aims to develop custom designed anticancer therapeutic frameworks that are effective, stable, safe, and tumor targeted, based on the biocompatible TiIV metal. The Tshuva group has established that water stable phenolato TiIV complexes are especially effective as anticancer agents both in vitro and in vivo, with markedly reduced side effects. Optimal derivatives will be developed to combine activity, stability, and biological accessibility, by maintaining small steric bulk while incorporating strong binding donors and hydrophilicity. The mechanism of action will be investigated by chemical and biological methods, including analyzing bio-distribution, cellular pathways and targets, and interaction with bio-molecules. Specifically, the active metal centers will be linked to bioactive moieties through redox-sensitive S–S bonds to enable tumor targeting. Cell penetrating peptides will facilitate cellular penetration for redox-dependent release of the active species selectively in cancer cells; steroid moieties will direct selectivity to hormone-dependent cancer cell types. Since the combination of TiIV- with Pt-based drugs has shown synergistic effects, multi-active entities will include two or more metal centers, possibly also linked to a transport unit. In addition to linear conjugates, polymeric and dendritic assemblies, exploiting the enhanced permeability of cancer cells, will be constructed with theoretically unlimited options for targeted delivery of multiple active sites. Most importantly, flexible well-defined redox-sensitive cages, as well as rigid pH sensitive complex cages, constructed with customized 3D geometries, will enable specific targeting of any active compound or conjugate and selective dissociation only where desired. This study should yield superior anticancer drugs, while unraveling the mystery of their complex biochemistry, and will contribute to the development of novel chemical and medicinal research directions and applications.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores